# US 2021/0278393 A1 · Method for measuring single-cell biomass to predict clinical outcomes for stem cell transplant patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0278393 A1
- Document ID: US20210278393A1
- Status: Published application
- Kind: A1
- Application number: 16/330,554
- Filed: 2017-09-19
- Published: 2021-09-09
- Earliest claimed: 2016-09-19
- Assignees: Virginia Commonwealth University
- Applicants: Virginia Commonwealth University
- Inventors: Jason REED; Amir TOOR; Kevin LESLIE
- Web page: https://patentgrep.com/patent/US20210278393A1

## CPC

- G01N 33/505: {involving T-cells}
- G01N 33/5073: {Stem cells}
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61P 35/00: Antineoplastic agents
- G01N 21/45: using interferometric methods; using Schlieren methods
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 2201/06113: Coherent sources; lasers
- G01N 2201/08: Optical fibres; light guides
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods of determining the mass of T cells in stem cell transplant (SCT) recipients at risk of developing graft vs host disease (GVHD), and tumor (e.g. melanoma) cells in patients at risk of developing drug resistant tumors, using Live-Cell Interferometry (LCI) so that treatment may be appropriately modulated. High Speed LCI (HSLCI) apparatuses to conduct the cell mass measurements are also provided.

## Claims

### Claim 1

A method for predicting the risk of and prophylactically treating graft-versus-host disease (GVHD) in a subject in need thereof, comprising the steps of:
measuring the cell biomass of CD3+ T cells isolated from a biological sample obtained from said subject;
comparing the measured cell biomass to a reference value obtained from a control subject not at risk for GVHD;
determining that said subject is at risk for developing GVHD when the measured cell biomass is higher than the reference value; and
administering an immunosuppressant therapy to said subject determined to be at risk for developing GVHD.

### Claim 2 (depends on 1)

The method of claim 1, wherein said subject has had a stem cell transplantation.

### Claim 3 (depends on 2)

The method of claim 2, wherein said control subject is a transplant donor.

### Claim 4 (depends on 1)

The method of claim 1, wherein said measuring step is performed using live-cell interferometry (LCI).

### Claim 5 (depends on 4)

The method of claim 4, wherein said LCI is high speed LCI (HSLCI).

### Claim 6

A method of detecting resistance to at least one anticancer drug in a subject in need thereof and treating the subject accordingly, comprising
i) administering the at least one anticancer drug to the subject;
ii) performing HSLCI to measure a cell biomass value of tumor cells isolated from a biological sample obtained from the subject;
iii) comparing the tumor cell biomass value to a reference tumor cell biomass value obtained from a control group of tumor cells that are not resistant to the at least one anticancer drug;
iv) determining that the subject is resistant to the at least one anticancer drug when the cell biomass value is greater than the reference cell biomass value or determining that the subject is not resistant to the at least one anticancer drug when the cell biomass value is less than or equal to the reference cell biomass value; and
v) discontinuing administration of the at least one anticancer drug to the subject when the subject is determined in step iv) to be resistant to the at least one anticancer drug or continuing administration of the at least one anticancer drug to the subject when the subject is determined in step iv) to not be resistant to the at least one anticancer drug.

### Claim 7 (depends on 6)

The method of claim 6, further comprising, after the step of discontinuing, administering at least one different anticancer drug to the subject.

### Claim 8 (depends on 6)

The method of claim 6, wherein said biological sample is a blood sample.

### Claim 9 (depends on 6)

The method of claim 6, wherein said anticancer drug is a kinase inhibitor or an immunotherapeutic agent.

### Claim 10

A method of detecting resistance to at least one melanoma drug in a subject in need thereof and treating the subject accordingly, comprising
i) administering the at least one melanoma drug to the subject;
ii) measuring a cell biomass value of tumor cells isolated from a biological sample obtained from the subject;
iii) comparing the tumor cell biomass value to a reference tumor cell biomass value obtained from a control group of tumor cells that are not resistant to the at least one melanoma drug;
iv) determining that the subject is resistant to the at least one melanoma drug when the cell biomass value is greater than the reference cell biomass value or
determining that the subject is not resistant to the at least one melanoma drug when the cell biomass value is less than or equal to the reference cell biomass value; and
v) discontinuing administration of the at least one melanoma drug to the subject when the subject is determined in step iv) to be resistant to the at least one melanoma drug or
continuing administration of the at least one melanoma drug to the subject when the subject is determined in step iv) to not be resistant to the at least one melanoma drug.

### Claim 11 (depends on 10)

The method of claim 10, further comprising, after the step of discontinuing, administering at least one different melanoma drug to the subject.

### Claim 12 (depends on 10)

The method of claim 10, wherein said biological sample is a blood sample.

### Claim 13 (depends on 10)

The method of claim 10, wherein said measuring step is performed using LCI.

### Claim 14 (depends on 13)

The method of claim 13, wherein said LCI is HSLCI.

### Claim 15

A method of selecting and administering one or more drugs or combination of drugs for treatment of a patient having a cancer that is resistant to one or more previously administered drugs, comprising
I) identifying a group of candidate drugs or combination of drugs that differ from the one or more previously administered drugs,
II) performing an HSLCI analysis of a biological sample having resistant cancer cells obtained from the patient to obtain a plurality of dose response curves for each candidate drug or combination of drugs in the group of candidate drugs or combination of drugs,
wherein the plurality of dose response curves is obtained at
i) a highest concentration of each candidate drug or combination of drugs equal to a peak serum concentration tolerated by patients, and
ii) one or more lower concentrations of each candidate drug or combination of drugs, each of which is lower than the highest concentration;
III) selecting for administration a drug or combination of drugs that inhibits growth of the resistant cancer cells at the lowest of the one or more lower concentrations that are tested; and
IV) administering the one or more drugs or combinations of drugs to the patient.

### Claim 16 (depends on 15)

The method of claim 15, wherein said cancer is melanoma.

### Claim 17 (depends on 16)

The method of claim 16, wherein said one or more drugs or combination of drugs is one or more kinase inhibitors or combination of kinase inhibitors.

### Claim 18

A high-speed live-cell interferometry (HSLCI) apparatus, comprising
i) a camera with a positionable camera objective;
ii) a quantitative phase detector;
ii) a moveable observation chamber for containing a cell sample;
iii) an autofocus component configured to continuously maintain the sample within an operational depth of focus of the microscope objective,
wherein the autofocus component comprises
a) a light source;
b) a microcontroller feedback loop configured to receive a positional signal transmitted from the camera objective and calculate and transmit an offset signal;
c) a precision actuator configured to receive the offset signal from the microcontroller feedback loop and adjust a position of the microscope objective in response to the offset signal; and
d) an electronic system configured to coordinate motion of the moveable observation chamber and light emitted from the light source; and
iv) a processor configured to process phase images obtained from the camera.

### Claim 19 (depends on 18)

The method of claim 18, wherein the light source is a pulsed light source.

### Claim 20 (depends on 19)

The method of claim 19, wherein the pulsed light source is an electronically gated LED, an electronically modulated laser, or a flash lamp.

### Claim 21 (depends on 18)

The method of claim 18, wherein the light source is an optical fiber.

### Claim 22 (depends on 18)

The method of claim 18, wherein the light source is a laser.

### Claim 23 (depends on 18)

The method of claim 18, wherein the cell sample comprises single isolated cells, cell clusters, or organoids.

### Claim 24 (depends on 18)

The method of claim 18, wherein the cells are attached to the chamber surface, suspended in solution or within a solid transparent matrix material

### Claim 25 (depends on 24)

The method of claim 24, wherein the solid transparent matrix material is gelatin.

### Claim 26 (depends on 18)

The method of claim 18, wherein the autofocus component is a coaxial optical beam deflection displacement sensor.

### Claim 27 (depends on 18)

The method of claim 18, wherein the precision actuator is a piezo actuator.

### Claim 28

A live cell interferometric measurement apparatus, comprising:
a means to image cells in a volume;
means to compute cell mass based on images of cells; and
a laser autofocus feature for focusing the imaging means on the cells in the volume.
